CDK12 and bone metastasis: Patients with CDK12 mutations were numerically more likely to present with higher Gleason score (8 including pattern 5 or higher, 94.4% vs. 70.2%) than those without CDK12 mutations, but with no apparent differences between these groups in age at mCRPC diagnosis (71 vs. 73 years), rate of positive family history (6.7% vs. 6.3%), and the site of metastasis (lymph node metastasis 63.2% vs. 53.2%; bone metastasis without other metastasis 31.6% vs. 37.9%).